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Abstract 24 
 Isothermal titration calorimetry (ITC) is a powerful technique able to evaluate the 25 
energetics of target-drug binding within the context of drug discovery. In this work the 26 
interactions of RNAs reproducing bacterial and human ribosomal A-site, with two well-known 27 
antibiotic aminoglycosides, Paromomycin and Neomycin, as well as several Neomycin-28 
dinucleotide and -diPNA conjugates, have been evaluated by ITC and the corresponding 29 
thermodynamic quantities determined. The comparison of the thermodynamic data of 30 
aminoglycosides and their chemical analogues allowed to select Neomycin-diPNA conjugates 31 
as the best candidates for antimicrobial activity. 32 
 33 
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INTRODUCTION 37 
 38 
 Discovery of new drugs can be extremely helped by the thermodynamic measurements 39 
of the binding interactions with biological targets by assisting high-throughput screening of 40 
chemical libraries, by accelerating the lead optimization process, also for the fundamental 41 
understanding of the drug-target mechanism (Ladbury et al., 2010). In this context, increasing 42 
improvements in the accuracy and sensitivity of instrumentation are permitting that isothermal 43 
titration calorimetry (ITC) becomes the technique of choice when full thermodynamic profile 44 
is valuable (Holdgate, 2007). Commonly used for proteins, until recently, ITC was applied to 45 
the study of nucleic acids, and in particular, of RNA-drug complexes (Pilch et al., 2003; Feig, 46 
2004). An evident advantage of the technique is the simultaneous determination of the 47 
thermodynamic binding constant (Kb) closely related to free energy  variation (ΔG), the 48 
enthalpy (ΔH) and the entropy (ΔS) variations and also the binding stoichiometry (N) from a 49 
single well designed experiment (Ladbury, 2004). It should be mentioned, however, that other 50 
common techniques are able to measure the ratio between the bound and free species 51 
concentrations and, then, to provide the stoichiometry and the binding constant of the studied 52 
interaction, but ΔH quantity cannot be directly measured. Thus, ITC seems to be the best 53 
experimental approach to get a reliable and complete thermodynamic description of the 54 
interaction of interest. 55 
 The vast knowledge acquired on RNA biochemistry, particularly, the elucidation of the 56 
ribosome structure and the gene decoding at atomic level (Wimberly et al., 2000; Carter et al., 57 
2000) has fuelled the interest on RNA-based therapies (Kole et al., 2012). Similarly to proteins, 58 
RNA can fold into a broad range of different structures, which can be targeted by small-59 
molecules (Aboul-ela et al., 2010). In this sense, the aminoglycosides such as Paromomycin 60 
and Neomycin (Fig. 1) are the paradigm of therapeutically useful RNA ligands (Hermann, 61 
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2005). Aminoglycosides, typically formed by an aminocyclitol unit (2-deoxystreptamine in 62 
Paromomycin and Neomycin, Fig. 1) attached to one or more amino sugars via glycosidic 63 
linkages, are a class of broad-spectrum antibiotics against aerobic gram-negative bacteria, 64 
which exert their activity by binding to ribosomal RNA (rRNA). X-ray crystallography (Carter 65 
et al., 2000; Vicens and Westhof, 2001; François et al., 2005) and NMR (Lynch et al., 2003) 66 
studies provided a very precise picture of the molecular binding mechanisms of 67 
aminoglycosides. These antimicrobials target the A-site within bacterial 16S rRNA of the small 68 
ribosome subunit, by binding to a three-adenine internal loop, involved in the correct 69 
deciphering of the mRNA. Upon binding, aminoglycosides provoke the structural 70 
rearrangement of the site, fact that eventually forge the ribosomal proofreading mechanism and 71 
lead to miscoding and inhibition of protein synthesis. 72 
 The clinical use of aminoglycosides had been depreciated by toxicity, target 73 
promiscuity and the appearance of resistance mechanisms, but the alarming decrease in the 74 
activity of the current antibiotic repertoire has renewed the interest for their chemical analogues 75 
(Hainrichson et al., 2008). Among many other derivatives, aminoglycoside–oligonucleotide 76 
conjugates have recently been considered as specific ligands of bacterial and viral RNA (Riguet 77 
et al., 2005; Hyun et al., 2006; Charles et al., 2007; Kiviniemi and Virta, 2011) due to the 78 
additional chemical recognition properties conferred by oligonucleotide strands. Here, we 79 
decided to contribute to this trend by developing novel aminoglycoside-oligonucleotide 80 
conjugates (Alguacil et al., 2010), and gaining insight on how these analogues could act as 81 
specific RNA binders. We hypothesized that aminoglycosides derivatized with dinucleotide or 82 
diPNA moieties could improve the target selectivity because their pending nucleobase units 83 
could procure additional interactions with the RNA nucleobases close to the aminoglycoside 84 
binding site by canonical or non—canonical hydrogen bonding, or by procuring complex 85 
interactions as those observed in tertiary RNA motifs. As a first step, we intended to study the 86 
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interaction of these aminoglycoside conjugates with the validated target of aminoglycosides, 87 
that is, the A-site ribosomal RNA. To this aim, inspired by the pioneer work of Pilch and col. 88 
(Kaul and Pilch, 2002; Pilch et al., 2003; Kaul et al., 2003; Kaul et al., 2005), here we present 89 
the results of ITC experiments on the interaction of the aminoglycosides Paromomycin and 90 
Neomycin, as well as the Neomycin-conjugates depicted in Fig. 1 with surrogates of bacterial 91 
(RNAEC) and human cytoplasmic rRNA (RNAHS). These two 27-mer hairpin oligonucleotides 92 
(Fig.2) were designed by the Puglisi group (Fourmy et al., 1996; Lynch and Puglisi, 2001; 93 
Lynch et al., 2003) to mimic the aminoglycoside binding sites in bacterial and human rRNA, 94 
respectively. The consensual bacterial target (RNAEC) preferred by antibiotic aminoglycosides 95 
contains an asymmetric internal loop formed by three adenines (A1408, A1492, and A1493, 96 
according to the numbering of Escherichia coli rRNA sequence, Fig. 2). Instead, in the 97 
eukaryotic A-site one of the adenines (A1408) is replaced by a guanine (G1408). Structural studies 98 
showed that this single nucleobase change (also present in some resistant bacteria) explain why 99 
human ribosomes are less sensitive to deleterious effects of aminoglycosides because reduces 100 
the affinity of aminoglycosides for rRNA (Lynch and Puglisi, 2001; Kondo et al., 2006). 101 
Herein, we determined comparative affinities and thermodynamic values of our new analogues 102 
for the bacterial vs. the human target, as a first step to assess their antibiotic activity and reduced 103 
toxicity on humans. 104 
 105 
MATERIALS AND METHODS 106 
 107 
Instruments 108 
 Titrations were performed by means of an isothermic titration microcalorimeter 109 
MicroCal VP-ITC (MicroCal, LLC, Northampton, Ma, USA) equipped with a 1.4047 mL cell. 110 
A vacuum system ThermoVac, Microcal Inc. (MicroCal, LLC, Northampton, Ma, USA) was 111 
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used to degas the solutions. pH was measured with a Crison micro-pH 2002 potentiometer 112 
(Crison Instruments, Alella, Spain) equipped by a Crison 5014 combination electrode with a 113 
precision of ±0.1 mV (±0.002 pH units). The electrode system was standardized with ordinary 114 
aqueous buffers of pH 4.01 and 7.00. 115 
 116 
Chemicals 117 
 The two oligoribonucleotides mimicking the bacterial (RNAEC) and human cytoplasm 118 
(RNAHS) A-site rRNA (Fourmy et al., 1996; Kaul et al., 2003; Kaul et al., 2005) (Fig. 2) were 119 
prepared by solid-phase synthesis and conveniently purified by semipreparative HPLC. The 120 
compound purity has been tested by HPLC before use. Paromomycin sulfate and Neomycin 121 
trisulfate (> 98%) were from Sigma-Aldrich and used as received. Neomycin-dinucleotide 122 
(Neomycin-TT and Neomycin-AA) and -diPNA (Neomycin-tt and Neomycin-aa) conjugates 123 
(Fig. 1) were synthesized in house as described previously (Alguacil et al., 2010). 124 
 125 
Working solutions 126 
 A mixture of sodium cacodylate 10 mM, EDTA 0.1 mM and NaCl 150 mM adjusted at 127 
pH 5.5 has been used as the buffer solution. Both titrant and titrated solutions have been 128 
dissolved in this buffer in all instances. For titrations involving the RNAEC the concentration 129 
was 10 µM for the RNA and 200 or 300 µM for the ligands. In the case of the RNAHS titrations 130 
the concentration was 20 µM for the RNA and 500 µM for the ligands.  131 
  132 
 133 
 134 
ITC measurements 135 
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 The RNA solutions were heated at 90ºC in a sand bath and cooled down slowly, that is, 136 
the sample achieves the thermal equilibrium with the ambient temperature by spontaneous 137 
losing heat process until room temperature (about 20 ºC). Both titrant and titrated solution were 138 
deoxigenated before use. Successive volumes of 10 μL (0.5 μL s-1) of ligand solution 139 
(aminoglycosides, dinucleotide- or diPNA-conjugates) were added to the titration cell filled 140 
with the target solution (RNAEC or RNAHS). At least, three independent titrations were carried 141 
out for each ligand-target combination. Background titrations consisting in identical titrant 142 
solutions with the reaction cell filled just with the buffer solution were performed to determine 143 
the background heat, due to the ligand dilution and the syringe rotation. In all instances the 144 
working temperature was 25±0.2 ºC. The obtained data were analyzed through the Origin 7.0 145 
software supplied by Microcal. The ITC data were collected automatically and analyzed to get 146 
the N, ΔH, Kb, ΔG and ΔS values associated to the interaction. All the data have been fitted 147 
with Origin and Setphat/Nitpic software. No significant differences in final results have been 148 
observed using these algorithms and, then, data shown in Tables 2 and 3 are those from Origin 149 
(two binding sites mode in all instances except for Neomycinaa/RNAHS for which the 150 
sequential binding site mode has been used) 151 
 152 
RESULTS AND DISCUSSION 153 
 154 
 It is well known that ITC measurements are strongly unspecific since any chemical 155 
process is able to generate or consume an amount of heat. Very often, several concomitant 156 
reactions are involved in interactions with biological interest and all of them can significantly 157 
contribute to the measured heat (Zhang et al., 2000; Garrido et al., 2011). Particularly, the gain 158 
or loss of protons in the frame of the global process could be relevant in the final result. Then, 159 
to get biologically meaningful quantities, the experimental conditions of measurements should 160 
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be as close as possible to the biological environment when the interaction of interest will be 161 
done.   162 
 Pilch and col. determined the acidity constants of protonated amino groups present in 163 
Paromomycin and Neomycin and demonstrated that all of them are essentially protonated at 164 
pH 5.5 (Kaul et al., 2003). Therefore, the authors proposed sodium cacodylate (pH=5.5) as the 165 
buffer agent for ITC titrations of RNA with Paromomycin because of the absence of ligand 166 
proton exchange and, also, the very low buffer dissociation heat (Goldberg et al., 2002; Kaul 167 
et al., 2003). Moreover, to avoid the effect of the eventual presence of metal ions traces a 168 
complexing agent, EDTA, was added to the buffer solution and, also, the ionic strength was 169 
adjusted to the physiological ionic concentration with NaCl. Working in this way, the derived 170 
binding parameters should be as close as possible to those of the pure aminoglycoside-RNA 171 
interactions. Since Paromomycin and Neomycin differ only in the 6’ substituent (OH and NH3+, 172 
respectively), they are able to illustrate the effect of the global charge of the ligand in the 173 
binding behaviour with RNA, Fig. 1.  174 
 As a preliminary reference, Table 1 summarizes the literature binding constants referred 175 
to Paromomycin and Neomycin interactions with both RNAEC and RNAHS that were obtained 176 
with different experimental techniques and working conditions. Overall, it is noted that 177 
affinities of both aminoglycosides are higher for the bacterial RNAEC than for the human target 178 
and, Neomycin shows the higher binding constants for the two tested targets. Paromomycin, 179 
Neomycin and the Neomycin-conjugates depicted in Fig. 1 have been selected for this study. 180 
The buffer recommended by Pilch et col. (Kaul et al. 2003) has been also used in this work for 181 
all studied aminoglycosides and conjugates under the assumption that the ammonium groups 182 
of conjugates show pKa values close enough to those of the parent compound. In addition, at 183 
the selected pH the ionization of the nucleobases thymine and adenine present in conjugates 184 
can be considered nearly negligible (for thymine-N3, pKa=10.5, and for protonated adenine-185 
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N1, pKa=3.9; Saenger, 1984). Thus, the net charge for Paromomycin is +5, for Neomycin and 186 
its diPNA conjugates it is +6, and it is +4 for Neomycin-dinucleotide conjugates.  187 
 188 
Aminoglycosides-RNAEC interactions  189 
 190 
Results achieved for Paromomycin and Neomycin are summarized in Figure 3 and Table 2 191 
agree with those from literature obtained in the same experimental conditions (Table 1; Kaul 192 
et al., 2005). Both compounds show two main interaction events and the final results are 193 
consistent whichever the fitting algorithm was used. As noted previously for Paromomycin 194 
(Kaul et al., 2003), only this first event with the highest Kb and a stoichiometry (N1) of 195 
approximately 1has biological relevance because it relates to the specific binding of 196 
aminoglycosides to the RNA bulge site, thus it is useful for comparing affinities. The second 197 
drug interaction event, with an stoichiometry (N2) of approximately 2-3 and an affinity constant 198 
(Kb2) two orders of magnitude lower can be ascribed to unspecific binding of aminoglycosides 199 
to RNA (electrostatic and secondary interactions). This second binding event could be of 200 
biological relevance when working with wild RNAs, but it is not significant enough in 201 
experiments performed using small RNA surrogates, which reproduce appropriately the 202 
aminoglycoside binding site only.  203 
 The complete thermodynamic signatures for the first binding event are depicted in Fig. 204 
4. The breakdown of the overall binding affinity into its constituents values of enthalpy and 205 
entropy provides useful guidelines for deducing structure-activity relationships (Ladbury et al., 206 
2010; Chaires, 2008). A glance on the relative magnitudes of the enthalpic, ΔH, and entropic, 207 
TΔS, terms associated to the first interaction events shows the preponderance of the entropic 208 
one. This result seems to contravene with the substantial binding interactions that are 209 
established between the natural aminoglycosides and the bacterial A-site rRNA as shown by 210 
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the diffraction X-ray (François et al., 2005) and NMR (Fourmy et al., 1996) studies. 211 
Nevertheless, this trend was characteristic for minor groove binders of nucleic acids (François 212 
et al., 2005). Thus, the results would be mostly explained by the structural rearrangement that 213 
the aminoglycoside produces when binds into the RNA bulge which results into the 214 
displacement of the adenines A1492 and A1493 to the minor groove of the helix. This provokes 215 
the unstacking of the adenines which entails an enthalpy penalty. Moreover, the dependence of 216 
the binding affinities on the ionic strength (Kaul and Pilch, 2002) suggests that the electrostatic 217 
interactions play a significant role. Thus, since they produce the release of counterions from 218 
the RNA, there is an increase of the net entropy variation. Finally, it should be pointed out that 219 
target and ligand desolvation processes also alter the organized water network around both 220 
entities resulting in a significant entropic gain. 221 
 Values gathered in Table 2 point out Neomycin as the most effective natural 222 
aminoglycoside, as it binds to the RNA with higher affinity than Paromomycin (aprox. 10-fold 223 
in this study, 7-fold according to Kaul et al., 2006). The enhanced binding affinity of Neomycin 224 
with respect to Paromomycin is clearly related to the presence of a 6’-amino instead of a 225 
hydroxyl group, which results in a more favorable enthalpy. 226 
 With respect to conjugates, the diPNA-containing (Neomycin-tt and Neomycin-aa) 227 
show Kb1 values of the same order than the natural aminoglycoside Paromomycin but one order 228 
of magnitude lower than that of Neomycin, Table 2. As diPNA-conjugates contain the same 229 
number of amino groups than Neomycin, their lower affinity should be attributed to the global 230 
effect of the polyamide chain. Notably, the comparison of the first event thermodynamic 231 
quantities shows that the diPNA-conjugates enthalpic term is similar to that for Neomycin, 232 
being higher for Neomycin-aa than for Neomycin-tt. It is well known that the formation of new 233 
bonds, mainly hydrogen bonds but also van der Waals or polar interactions, favors the ΔH term. 234 
Thus, an increase of enthalpy contribution points out an increment in the number and/or 235 
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strength of the ligand-target interactions, and probably explain the lower Kb1 value of 236 
Neomycin-aa by rapport to Neomycin-tt. By contrast, the dinucleotide-conjugates (Neomycin-237 
AA and Neomycin-TT) show a lower affinity than the diPNA-conjugates. Their enthalpic 238 
contributions are significantly lower to that of the unsubstituted Neomycin, but the entropic 239 
terms are similar. Thus, low affinity could be attributed either to their lower positive charge 240 
with respect Neomycin and diPNA-conjugates, or to that the array of the polar groups does not 241 
favor the interaction with RNA. 242 
 243 
 244 
Aminoglycosides-RNAHS interactions 245 
 246 
The behaviour of ligands with respect the RNAHS, an eukaryote target, has been also studied 247 
to evaluate the selectivity, that is, the ratio between the affinities of each ligand with both 248 
prokaryote and eukaryote targets. This is a key question for estimating the potential activity of 249 
the compounds as antibiotics since the effectiveness as antimicrobial agents is clearly related 250 
to the specificity of the rRNA-targeting molecules for the bacterial versus human ribosomes 251 
(Kondo et al., 2007). The two natural aminoglycosides as well as the diPNA-conjugates with 252 
higher affinity for the bacterial target (Neomycin-tt and Neomycin-aa) have been considered 253 
in this part of work. Note that Kb1 for Paromomycin-RNAHS complex in the experimental 254 
conditions reported before (Table 1) is consistent with that obtained in our laboratory (Table 255 
3).  256 
 The titration curves depicted in Fig. 5 show also, at least, two interaction steps with 257 
RNAHS but the shape of the ITC curves strongly differs from those obtained with the prokaryote 258 
RNAEC. As expected, the affinity of the aminoglycosides and the diPNA-conjugates for the 259 
human target is at least one order lower than for the prokaryote target, confirming what was 260 
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reported for aminoglycosides and their analogues (Kaul et al., 2005; Kondo et al., 2007). For 261 
the natural aminoglycosides, Paromomycin and Neomycin, the first event involves lower 262 
enthalpic contribution than the second one despite the associated binding constant is higher 263 
(Kb1>Kb2). Neomycin shows the highest target affinity, Kb1 value, miming the observed 264 
behaviour with the prokaryote RNAEC. diPNA-conjugates show similar Kb values, close to that 265 
of Paromomycin, but an order lower than Neomycin, similarly to what was observed in 266 
bacterial RNA complexes. Neomycin-tt origins successive binding steps of decreasing 267 
associated ΔH values. Only the two first events, the most significant ones, are included in Table 268 
3. Finally, Neomycin-aa shows, at least, three interaction steps. This third event was not 269 
observed in the other studied systems, and it could not be attributed any physical meaning. A 270 
plausible explanation was the precipitation of RNA as a result of the saturation by positively-271 
charged aminoglycosides (a peak broadening was observed after the second binding event), but 272 
any other process could be also possible. The very low RNAHS concentration (20 μM) 273 
prevented to visualize any precipitation process. Then, Neomycin-aa binds RNAHS in a 274 
different way than other tested aminoglycosides showing a significantly higher enthalpy 275 
variation. The complete thermodynamic signatures of all studied first interaction events are 276 
shown in Fig. 6 277 
 278 
Comparison of aminoglycosides and conjugates interactions with eukaryote and 279 
prokaryote targets 280 
 281 
The selectivity of aminoglycosides and conjugates for the bacterial versus the human RNA was 282 
estimated by comparing the thermodynamic values obtained in the two sets of experiments (see 283 
Tables 2 and 3). Due to the fact that binding interactions were studied on RNA surrogates of 284 
wild ribosomal RNA, the thermodynamic values assigned to the second interaction were not 285 
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probably a robust estimation of unspecific bindings. So, in order to estimate the selectivity of 286 
bacterial vs. human RNA we only considered the first interaction. At this point it should be 287 
emphasized that, from the Holdgate diagram point of view (Holdgate, 2007), all the considered 288 
interactions show thermodynamic parameter values with biological relevance, being all of the 289 
compounds more akin to bacterial target. Notably, although Neomycin is the compound with 290 
the highest selectivity for the bacterial versus the human RNA, diPNA-conjugates show a better 291 
selectivity than Paromomycin. 292 
 For Paromomycin and Neomycin the differences between the two targets are, mainly, 293 
of the enthalpic origin since the entropic terms are similar. The difference between the binding 294 
constants is not attributable to a higher number of electrostatic interactions by Neomycin than 295 
by Paromomycin since they contribute mainly to the entropic term because of the release of 296 
counterions to the media (Kaul et al., 2005). Then, the molecular origin of the difference in the 297 
enthalpic contributions should be due to the structural differences between the two targets 298 
(Lynch and Puglisi, 2001). Thus, the binding of Paromomycin to the A-site of the prokaryote 299 
target origins a conformational change in the A1408, A1492 and A1493 residues resulting in several 300 
stacking interactions which, from the energetic point of view, favour the binding process. By 301 
contrast, in the eukaryote target the structure of the guanine internal loop hinders the binding 302 
of the aminoglycoside. 303 
 Notably, according to our data, the two diPNA-conjugates show different modes of 304 
binding to the RNAHS target. The enthalpic term in both conjugates is higher for the eukaryote 305 
target than for the prokaryote one, but the entropic term is significantly lower, Fig. 6. Then, the 306 
lower affinity of the conjugated ligands to the human RNA is from an entropic origin. 307 
 Table 4 shows the ratio between the binding constants of the studied ligands with the 308 
two targets and gives information on the selectivity of the ligands. Thus, all the tested 309 
aminoglycosides show a higher preference for the prokaryote target being that of Neomycin 310 
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the highest one. Interestingly, the selectivities of both diPNA conjugates are similar but 311 
significantly higher than for Paromomycin. In some way, this result supports the working 312 
hypothesis that the derivatization of aminoglycosides with nucleobase units can improve their 313 
selectivity by procuring additional interactions with RNA targets. The binding constants of 314 
Paromomycin and both Neomycin derivatives with each target are similar but Neomycin-aa 315 
shows a binding process mainly due to the enthalpic term whereas the remaining ligands were 316 
governed by the entropy. Probably, this fact is explained by a different interaction mode of the 317 
Neomycin-aa derivative, that originates in the distinctive binding properties of the pendant 318 
diPNA. Notably, Neomycin-aa that shows a slightly better selectivity than Neomycin-tt, it is 319 
also the aminoglycoside analogue with the highest enthalpic contribution to binding. This 320 
appears to corroborate the convenience that the selection of drug candidates should be guided 321 
not only by ΔG values, but also considering the ΔH/(TΔS) ratios because a higher enthalpic 322 
term guarantees a better selectivity (Kondo et al., 2007; Ladbury et al., 2010). 323 
 324 
CONCLUSIONS 325 
Here, the comparative thermodynamic analysis by ITC of the binding interaction of 326 
natural aminoglycosides and chemical analogues with A-site rRNA surrogates has permitted 327 
to select Neomycin-diPNA conjugates as potential lead compounds for antimicrobial activity. 328 
Although at a preliminary stage, this result seems to corroborate than it is possible to fine-tune 329 
the binding of aminoglycosides to their biological targets by incorporation of ancillary 330 
appendages. Work is in progress to further extend the set of aminoglycoside conjugates, and to 331 
assess their potential antimicrobial activity. 332 
 333 
 334 
 335 
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Figure captions  434 
 435 
Figure 1. Structure of aminoglycosides (Paromomycin and Neomycin), Neomycin-436 
dinucleotide (Neomycin-TT and Neomycin-AA) and -diPNA (Neomycin-tt and Neomycin-437 
aa) conjugates. 438 
 439 
Figure 2. Oligoribonucleotides mimicking the a) Escherichia coli (bacterial) A-site rRNA 440 
(RNAEC) and b) Human Cytoplasm Ribosomal A-site rRNA (RNAHS). The nucleotides of the 441 
internal loop are shown in bold and numbered according to the sequence of bacterial 16S 442 
rRNA. 443 
 444 
Figure 3. ITC curves for the interactions of Paromomycin, Neomycin and Neomycin 445 
derivatives with RNAEC. 446 
 447 
Figure 4. Thermodynamic signatures for the interactions of Paromomycin, Neomycin and 448 
Neomycin derivatives with RNAEC. Color code: ΔH1 (dark grey), -TΔS1 (light grey), ΔG1 449 
(black). 450 
 451 
Figure 5. ITC curves for the interactions of Paromomycin, Neomycin and Neomycin 452 
derivatives with RNAHS. 453 
 454 
Figure 6. Thermodynamic signatures for the interactions of Paromomycin, Neomycin and 455 
Neomycin derivatives with RNAHS. Color code: ΔH1 (dark grey), -TΔS1 (light grey), ΔG1 456 
(black). 457 
  458 
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 467 
Table 1 468 
Binding constants of the interaction of aminoglycosides with A-site rRNAs 469 
 470 
 Kb (M-1) 
 Paromomycin Neomycin 
Technique Bacterial Human Bacterial Human 
Fluorescence 
Fluorescence 
6.06×105 a 
2.10×106 b 4.55×105 a 3.90×105 b 1.89×107 a 3.00×107 b 3.85×106 a ---- 
UV-melting curves 2.50×107 c --- 2.60×108 c --- 
SPR 5.00×106 d --- 5.26×107 d --- 
ITC 
ITC 
ITC 
3.70×107 e 
4.34×106 f 
1.27×105 g 
2.40×106 e 
--- 
--- 
--- 
4.76×106 f 
1.23×106 g 
--- 
--- 
--- 
aExperimental conditions: a150 mM Na+, pH 7.5 (Ryu et al., 2001). 471 
bExperimental conditions: 100 mM Na+, pH 7.5 (Kaul et al., 2005; Kaul et al., 2006) 472 
cExperimental conditions: 150 mM Na+, pH 5.5 (Pilch et al., 2003) 473 
dExperimental conditions: 150 mM Na+, pH 7.5 (Wong et al., 1998) 474 
eExperimental conditions: 150 mM Na+, pH 5.5 (Kaul et al., 2005) 475 
fExperimental conditions: 100 mM K+, 2 mM Mg2+, pH 7.0 (Ennifar et al., 2013) 476 
gExperimental conditions: 200 mM K+, 2 mM Mg2+, pH 7.0 (Ennifar et al., 2013) 477 
 478 
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 480 
Table 2 481 
Binding parameters of the studied ligands with RNAEC 482 
 483 
 Paromomycin Neomycin Neomycin-TT Neomycin-AA Neomycin-tt Neomycin-aa 
N1 1.1 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.0 0.8 ± 0.1 0.8 ± 0.0 
Kb1 (M-1) (1.7 ± 0.2) ×107 (2.1 ± 0.7) ×108 (1.3 ± 0.3) ×107 (2.2 ± 0.7) ×106 (5.7 ± 1.1) ×107 (3.4 ± 2.0) ×107 
ΔG1 (kcal·mol-1) -9.9 ± 0.2 -11.4 ± 0.2 -10.0 ± 0.1 -8.6 ± 0.2 -10.6 ± 0.1 -10.2 ± 0.3 
ΔH1 (kcal·mol-1) -3.1 ± 0.3 -5.4 ± 0.0 -2.8 ± 0.4 -3.4 ± 0.0 -4.1 ± 0.2 -6.2 ± 0.2 
-TΔS1 (kcal·mol-1) -6.7 ± 0.3 -6.0 ± 0.1 -6.9 ± 0.3 -5.2 ± 0.2 -6.5 ± 0.3 -4.0 ± 0.6 
N2 3.0 ± 0.5 3.0 ± 0.1 2.0 ± 0.8 2.6 ± 0.4 3.1 ± 0.1 2.6 ± 0.0 
Kb2 (M-1) (3.0 ± 0.5) ×105 (7.6 ± 0.7) ×105 (8.2 ± 0.8) ×105 (1.2 ± 0.4) ×105 (2.3 ± 0.7) ×105 (2.0 ± 0.0) ×105 
ΔG2 (kcal·mol-1) -7.5 ± 0.0 -8.0 ± 0.0 -8.1 ± 0.0 -6.9 ± 0.2 -7.3 ± 0.2 -7.2 ± 0.0 
ΔH2 (kcal·mol-1) -2.1 ± 0.5 -4.5 ± 0.3 -0.8 ± 0.6 -1.0 ± 0.4 -4.5 ± 0.3 -6.6 ± 0.1 
-TΔS2 (kcal·mol-1) -5.4 ± 0.6 -3.5 ± 0.4 -7.3 ± 0.6 -5.9 ± 0.2 -2.8 ± 0.4 -0.6 ± 0.1 
Experimental conditions: 10 mM sodium cacodylate, 0.1 mM EDTA, 150 mM NaCl, pH 5.5, 25 ± 0.2 ºC 
 484 
  485 
25 
 
 486 
Table 3  487 
Binding parameters of the studied ligands with RNAHS 488 
 489 
 Paromomycin a Neomycin a Neomycin-tt a Neomycin-aa a,b 
N1 1.5 ± 0.2 1.3 ± 0.0 1.2 ± 0.1 --- 
Kb1 (M-1) (5.2 ± 2.1) × 106 (1.7 ± 0.2) × 107 (7.3 ± 3.0) × 106 (3.7 ± 1.8) × 106 
ΔG1 (kcal·mol-1) -9.1 ± 0.2 -9.9 ± 0.0 -9.3 ± 0.3 -8.9 ± 0.3 
ΔH1 (kcal·mol-1) -0.6 ± 0.3 -2.7 ± 0.0 -4.9 ± 0.1 -7.3 ± 0.0 
-TΔS1 (kcal·mol-1) -8.5 ± 0.5 -7.2 ± 0.0 -4.4 ± 0.3 -1.6 ± 0.3 
N2 2.3 ± 0.7 2.1 ± 0.1 2.8 ± 0.1 --- 
Kb2 (M-1) (8.2 ± 1.6) × 105 (1.7 ± 0.2) × 105 (1.1 ± 0.0) × 105 (9.5 ± 2.4) × 105 
ΔG2 (kcal·mol-1) -6.7 ± 0.2 -7.1 ± 0.0 -6.9 ± 0.0 -8.1 ± 0.2 
ΔH2 (kcal·mol-1) -2.2 ± 0.3 -5.3 ± 0.2 -5.0 ± 0.2 -4.0 ± 0.0 
-TΔS2 (kcal·mol-1) -4.5 ± 0.4 -1.9 ± 0.3 -1.8 ± 0.3 -4.1 ± 0.2 
aExperimental conditions: 10 mM sodium cacodylate, 0.1 mM EDTA, 150 mM NaCl, pH 5.5, 25 ± 0 2 ºC  
bIn this case, curves could be only adjusted to a sequential binding mode, up to a total of three calorimetric events. 
 490 
  491 
26 
 
 492 
Table 4 493 
Estimation of selectivity for RNAEC vs RNAHS (Kb1 ratios) 494 
 495 
 Paromomycin Neomycin Neomycin-tt Neomycin-aa 
Kb1(RNAEC)/Kb1(RNAHS) 3 12 8 9 
 496 
